Intravenous iron therapy restores functional iron deficiency induced by infliximab

Journal of Crohn's and Colitis

Volumn 1, Issue 2, 2007, Pages 97-105

  Katsanos, Konstantinos ^a   Cavalier, Etienne ^b   Ferrante, Marc ^a   Van Hauwaert, Valérie ^a   Henckaerts, Liesbet ^a   Schnitzler, Fabian ^a   Katsaraki, Afroditi ^c   Noman, Maja ^a   Vermeire, Séverine ^a   Tsianos, Epameinondas V ^c   Rutgeerts, Paul ^a   Chapelle, Jean Paul ^a   Van Assche, Gert ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Anaemia; Erythropoietin; Inflammatory bowel disease; Infliximab; Iron sucrose; Safety

Indexed keywords

ANTIHISTAMINIC AGENT; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; HYDROCORTISONE; INFLIXIMAB; TRANSFERRIN RECEPTOR; VASCULOTROPIN;

ADULT; ALLERGIC REACTION; ANEMIA; ARTICLE; BLOOD PRESSURE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; DISEASE ACTIVITY; ENTERITIS; FEMALE; HUMAN; HYPOTENSION; IRON DEFICIENCY; IRON THERAPY; KINETICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 37249047451     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2007.08.005     Document Type: Article

References (51)

1. Macdougall I.C. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl 69 (1999) S61-S66
2. Afzali B., and Goldsmith D.J. Intravenous iron treatment in renal failure: friend and foe?. J Nephrol 17 (2004) 487-495
3. Macdougall I., Bailie G., Richardson D., et al. Worldwide safety profile of iron sucrose injection (Venofer) analysis of 1,004,477 patients from 1992 to 2001. J Am Soc Nephrol 12 (2001) 333A
4. Cavill I. Intravenous iron as adjuvant treatment: a two-edged sword?. Nephrol Dial Transplant 18 Suppl 8 (2003) viii24-viii28
5. Mamula P., Piccoli D., Susan P., et al. Total dose intravenous infusion of iron dextran for iron-deficiency anaemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 34 (2002) 286-290
6. Venofer Product Monograph (Vifor International, Switzerland). 2nd completely revised edition (April 2000)
7. Hickman M.A., Bernstein I.L., and Palascak J.E. Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran. Ann Allergy Asthma Immunol 84 (2000) 262-263
8. Rutgeerts P., Van Assche G., and Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126 (2004) 1593-1610
9. Rutgeerts P., Feagan B.C., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 598-601
10. Rutgeerts P. Efficacy of infliximab in Crohn's disease-induction and systematic of remission. Aliment Pharmacol Ther 13 (1999) 9-15
11. Van Assche G., Vermeire S., and Rutgeerts P. Medical treatment of inflammatory bowel diseases. Curr Opin Gastroenterol 21 (2005) 443-447
12. Demirturk L., Hulagu S., Yaylaci M., et al. Serum erythropoietin levels in patients with severe anaemia secondary to inflammatory bowel disease and the use of recombinant human erythropoietin inpatients with anaemia refractory to treatment. Dis Colon Rectum 38 (1995) 896-897
13. Kapsoritakis A.N., Koukourakis M.I., Sfiridaki A., et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 96 (2001) 776-781
14. Tsitsika A., Stamoulakatou A., Kafritsa Y., et al. Erythropoietin levels in children and adolescents with inflammatory bowel disease. J Pediatr Hematol Oncol 27 (2005) 93-96
15. Schreiber S., Howaldt S., Schnoor M., et al. Recombinant erythropoietin for the treatment of anaemia in inflammatory bowel disease. N Engl J Med 334 (1996) 619-623
16. Gasche C., Waldhoer T., Feichtenschlager T., et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anaemia. Am J Gastroenterol 96 (2001) 2382-2387
17. Roy C.N., Weinstein D.A., and Andrews N.C. 2002 E. Mead Johnson award for research in pediatrics lecture: the molecular biology of the anaemia of chronic disease: a hypothesis. Pediatr Res 53 (2003) 507-512
18. Oldenburg B., Koningsberger J.C., Van Berge Henegouwen G.P., et al. Iron and inflammatory bowel disease. Aliment Pharmacol Ther 15 (2001) 429-438
19. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 329 (2003) 9-22
20. Feelders R.A., Kuiper-Kramer E.P., and van Eijk H.G. Structure, function and clinical significance of transferrin receptors. Clin Chem Lab Med 37 (1999) 1-10
21. Ferrante M., Pierik M., Henckaerts L., et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis 12 (2006) 870-878
22. Gasche C., Reinisch W., Lochs H., et al. Anaemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci 39 (1994) 1930-1934
23. Gasche C., Lomer M.C.E., Cavill I., et al. Iron, anaemia, and inflammatory bowel diseases. Gut 53 (2004) 1190-1197
24. Gasche C., Dejaco C., Waldhoer T., et al. Intravenous iron and erythropoietin for anaemia associated with Crohn disease. Ann Intern Med 126 (1997) 782-787
25. Gasche C., Dejaco C., Reinisch W., et al. Sequential treatment of anaemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion 60 (1999) 262-267
26. Erichsen K., Ulvik R.J., Nysaeter G., et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 40 (2005) 1058-1065
27. Bodemar G., Kechagias S., Almer S., et al. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 39 (2004) 454-458
28. Jelkmann W., and Wiedemann G. Lack of sex dependence of the serum level of immunoreactive erythropoietin in chronic anaemia. Klin Wochenschr 67 (1989) 1218
29. Goldgerg M.A., and Schneider T.J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 269 (1994) 4355-4359
30. Johanssen H., Jelkmann W., Wiedemann G., et al. Erythropoietin/haemoglobin relationship in leukemia and ulcerative colitis. Eur J Haematol 43 (1989) 201-206
31. Kokot F., Grzeszczak W., Wiecek A., et al. Plasma erythropoietin levels in patients with stabilized function of the transplanted kidney. Pol Arch Med Wewn 85 (1991) 365-372
32. Montanaro D., Gropuzzo M., Tulissi P., et al. Effects of mycophenolate mofetil and azathioprine on the erythropoietin production in renal transplant receipients. Transplant Proc 33 (2001) 3253-3255
33. Jensen J.D., Hansen H.E., and Pedersen E.B. Increased serum erythropoietin level during azathioprine treatment in renal transplant recipients. Nephron 67 (1994) 297-301
34. Howarth J.E., Waters H.M., Shanks D., et al. Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin. J Clin Pathol 46 (1993) 41-44
35. Wolff M., and Jelkmann W. Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures. Ann Hematol 66 (1993) 27-31
36. Koutroubakis I.E., Karmiris K., Makreas S., Xidakis C., Niniraki M., and Kouroumalis E.A. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study. Eur J Gastroenterol Hepatol 18 (2006) 421-425
37. Papadaki H.A., Kritikos H.D., Gementzi C., et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 99 (2002) 1610-1619
38. Domenech E., Manosa M., Masnou H., et al. Infliximab for the treatment of chronic anaemia in Crohn's disease. Am J Gastroenterol 100 (2005) 496
39. Stasi R., and Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol 116 (2002) 334-337
40. Tam B.Y.Y., Wei K., Rudge J.S., et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 12 (2006) 793-800
41. Picaud J.C., Putet G., Salle B.L., et al. Supplementation en fer chez les enfants prematures traits par erythropoietine. Arch Pediatr 6 (1999) 657-664
42. Charytan C., Levin N., Al-Saloum M., et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis associated anaemia: North American clinical trial. Am J Kidney Dis 37 (2001) 300-307
43. Fishbane S., Ungureanu V.D., Maesaka J.K., et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28 (1996) 529-534
44. Stoves J., Inglis H., and Newstead C.G. A randomized study of oral vs. intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16 (2001) 967-974
45. Schroder O., Mickisch O., Seidler U., et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease-a randomized, controlled open-label, multicenter study. Am J Gastroenterol 100 (2005) 2503-2509
46. Feldman H.I., Santanna J., Guo W., et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13 (2002) 734-744
47. Gasche C. Anaemia in IBD: the overlooked villain. Inflamm Bowel Dis 6 (2000) 142-150
48. Wilson A., Reyes E., and Ofman J. Prevalence and outcomes of anaemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 116 7A (2004) 44S-49S
49. Kahraman S., Yilmaz R., Genctoy G., et al. Efficacy and safety of intravenous iron treatment for HCV-positive haemodialysis patients. Nephrol Clin Pract 100 (2005) c78-c85
50. Christodoulou D.K., and Tsianos E.V. Anaemia in inflammatory bowel disease-the role of recombinant human erythropoietin. Eur J Intern Med 11 (2000) 222-227
51. Thayu M., and Mamula P. Treatment of iron deficiency anaemia in pediatric inflammatory bowel disease. Curr Treat Options Gastroenterol 8 (2005) 411-417